These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25519783)

  • 1. Preventing HIV-associated tuberculosis with antiretroviral therapy: shut the stable door early!
    Lawn SD
    Int J Tuberc Lung Dis; 2015 Jan; 19(1):3-4. PubMed ID: 25519783
    [No Abstract]   [Full Text] [Related]  

  • 2. CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.
    Collins SE; Jean Juste MA; Koenig SP; Secours R; Ocheretina O; Bernard D; Riviere C; Calnan M; Dunning A; Hurtado Rúa SM; Johnson WD; Pape JW; Fitzgerald DW; Severe P
    Int J Tuberc Lung Dis; 2015 Jan; 19(1):50-7. PubMed ID: 25519790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States.
    Luetkemeyer AF
    Top HIV Med; 2010; 18(4):143-8. PubMed ID: 21107014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape.
    Fehr J; Nicca D; Goffard JC; Haerry D; Schlag M; Papastamopoulos V; Hoepelman A; Skoutelis A; Diazaraque R; Ledergerber B
    Infection; 2016 Aug; 44(4):521-9. PubMed ID: 26983974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing tuberculosis in differentiated care provision for people living with HIV.
    Pathmanathan I; Pevzner E; Cavanaugh J; Nelson L
    Bull World Health Organ; 2017 Jan; 95(1):3. PubMed ID: 28053356
    [No Abstract]   [Full Text] [Related]  

  • 7. Is early initiation of antiretroviral therapy important?
    Winslow DL
    AIDS; 2024 Jul; 38(8):1263-1264. PubMed ID: 38814713
    [No Abstract]   [Full Text] [Related]  

  • 8. [Simultaneous treatment of HIV and tuberculosis is possible and necessary].
    von der Maase S; Gerstoft J; Wejse C
    Ugeskr Laeger; 2014 Feb; 176(6A):V03130163. PubMed ID: 25347439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiretroviral treatment on the risk of tuberculosis during South Africa's programme expansion.
    Bachmann MO; Timmerman V; Fairall LR
    AIDS; 2015 Nov; 29(17):2261-8. PubMed ID: 26544699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.
    Lawn SD; Wood R; De Cock KM; Kranzer K; Lewis JJ; Churchyard GJ
    Lancet Infect Dis; 2010 Jul; 10(7):489-98. PubMed ID: 20610331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal voluntary HIV testing and immediate antiretroviral therapy.
    Wilson DP
    Lancet; 2009 Mar; 373(9669):1077-8; author reply 1080-1. PubMed ID: 19328991
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4+ cell count responses to antiretroviral therapy are not impaired in HIV-infected individuals with tuberculosis co-infection.
    Gupta RK; Brown AE; Zenner D; Rice B; Yin Z; Thomas HL; Pozniak A; Abubakar I; Delpech V; Lipman M
    AIDS; 2015 Jul; 29(11):1363-8. PubMed ID: 26091298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
    Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
    AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in HIV prevalence and the population-level effects of antiretroviral therapy in reducing tuberculosis incidence in South Africa.
    Sloot R; Maarman GJ; Osman M; Marx On Behalf Of The Desmond Tutu Tb Centre-Working Group Data Analysis And Modelling FM
    S Afr Med J; 2018 Jul; 108(8):12370. PubMed ID: 30182871
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberculin skin test conversion among HIV patients on antiretroviral therapy in Uganda.
    Kirenga BJ; Worodria W; Massinga-Loembe M; Nalwoga T; Manabe YC; Kestens L; Colebunders R; Mayanja-Kizza H
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):336-41. PubMed ID: 23407223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of antiretroviral therapy in low-resource settings.
    Bendavid E
    Lancet; 2008 Jul; 372(9635):288-9; author reply 289. PubMed ID: 18657700
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiretroviral therapy programmes in resource limited settings.
    del Rio C; Armstrong W
    BMJ; 2011 Nov; 343():d6853. PubMed ID: 22074712
    [No Abstract]   [Full Text] [Related]  

  • 20. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
    Gutierrez EB; Gomes V; Picone CM; Suga H; Atomiya AN
    HIV Med; 2009 Oct; 10(9):564-72. PubMed ID: 19785665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.